Hepatitis C virus in the human liver transplantation model

Slides:



Advertisements
Similar presentations
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
Advertisements

Volume 50, Issue 4, Pages (April 2009)
Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients  Nazia Selzner, Maha Guindi, Eberhard.
HCV & liver transplantation
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and.
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Engineering Human Peripheral Blood Stem Cell Grafts that Are Depleted of Naïve T Cells and Retain Functional Pathogen-Specific Memory T Cells  Marie Bleakley,
CD4+CD25+ Immunoregulatory T Cells
Volume 122, Issue 5, Pages (May 2002)
Volume 143, Issue 4, Pages e4 (October 2012)
Volume 132, Issue 2, Pages (February 2007)
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Volume 137, Issue 4, Pages (October 2009)
Volume 140, Issue 2, Pages e1 (February 2011)
Volume 141, Issue 4, Pages e6 (October 2011)
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
Rapid, Flow Cytometric Assay for NK Alloreactivity Reveals Exceptions to Rules Governing Alloreactivity  Dianne De Santis, Bree A. Foley, Elisabeth John,
Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis.
Volume 140, Issue 2, Pages e1 (February 2011)
Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non–genotype 1 infection by Julian Schulze zur Wiesch,
Volume 27, Issue 4, Pages (October 2007)
Volume 137, Issue 3, Pages e7 (September 2009)
Volume 134, Issue 5, Pages (May 2008)
Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients  Nazia Selzner, Maha Guindi, Eberhard.
Allogeneic hematopoietic cell transplant in HCV-infected patients
Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16α-bromoepiandrosterone (HE2000)  C. Reading,
Jean-Michel Pawlotsky, MD, PhD  Clinics in Liver Disease 
Volume 141, Issue 4, Pages e2 (October 2011)
Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission  Yongjun Tian,
Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Be Efficiently Expanded from Granulocyte Colony-Stimulating Factor–Mobilized Hemopoietic Progenitor.
Quasispecies tropism and compartmentalization in gut and peripheral blood during early and chronic phases of HIV-1 infection: possible correlation with.
Chronic HCV infection and the clonality of intrahepatic T cells
Volume 143, Issue 6, Pages e4 (December 2012)
Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome  Caroline Pical-Izard, Roberto.
Volume 38, Issue 2, Pages (February 2013)
Volume 153, Issue 5, Pages e2 (November 2017)
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.
Volume 48, Issue 1, Pages e5 (January 2018)
Cellular immune responses to recurring influenza strains have limited boosting ability and limited cross-reactivity to other strains  Y. Keynan, C.M.
Volume 132, Issue 2, Pages (February 2007)
T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient.
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C
Volume 127, Issue 3, Pages (September 2004)
Volume 19, Issue 2, Pages (February 2016)
Volume 39, Issue 4, Pages (October 2003)
In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.
A predominant Th1 type of immune response is induced early during acute Helicobacter pylori infection in rhesus macaques  Joseph J. Mattapallil, Satya.
Volume 137, Issue 4, Pages e6 (October 2009)
Volume 11, Issue 6, Pages (June 2012)
Volume 22, Issue 1, Pages (January 2014)
Volume 127, Issue 3, Pages (September 2004)
Immunopathogenesis of hepatitis C virus infection
Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients  Nazia Selzner, Maha Guindi, Eberhard.
Volume 147, Issue 4, Pages e8 (October 2014)
Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8+ T Cells and Memory Responses  Axel Kallies, Annie Xin, Gabrielle T.
Volume 117, Issue 4, Pages (October 1999)
Volume 123, Issue 4, Pages (October 2002)
Volume 121, Issue 5, Pages (November 2001)
Innate immunity and HCV
Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study  D. Goletti, S. Carrara,
Volume 29, Issue 4, Pages (October 2008)
ERAP1 allotypes shape the epitope repertoire of virus-specific CD8+ T cell responses in acute hepatitis C virus infection  Janine Kemming, Emma Reeves,
Volume 58, Issue 5, Pages (May 2013)
Volume 24, Issue 6, Pages (June 2016)
Volume 40, Issue 2, Pages (February 2014)
Volume 38, Issue 2, Pages (February 2013)
Volume 39, Issue 3, Pages (September 2003)
Presentation transcript:

Hepatitis C virus in the human liver transplantation model Hugo R. Rosen, MD  Clinics in Liver Disease  Volume 7, Issue 1, Pages 107-125 (February 2003) DOI: 10.1016/S1089-3261(02)00073-9

Fig. 1 Allograft biopsy findings at 1 and 5 years in HCV–positive liver transplant recipients, with findings at 5 years in HCV-negative patients. The majority of HCV-infected patients demonstrate histologic recurrence by year 1, and 20% have allograft cirrhosis by year 5. (From Gane EJ, Portmann BC, Naoumouv NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Eng J Med 1996;334:821–7; with permission.) Clinics in Liver Disease 2003 7, 107-125DOI: (10.1016/S1089-3261(02)00073-9)

Fig. 2 Hepatitis C virus kinetics during and after liver transplantation. Two representative patients demonstrating the most common pattern: rapid increase in viral load, reaching pretransplantation levels by day 4. (From Garcia-Retortillo M, Forns X, Feliu An, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35(3):680–7; with permission.) Clinics in Liver Disease 2003 7, 107-125DOI: (10.1016/S1089-3261(02)00073-9)

Fig. 3 Neighbor joining phylogenetic trees constructed from NS3 gene sequences (nt 3882-5202) of all study patients (severe [S1-S16] and mild [M1-16] recurrence). Distinct clusters of viral sequences corresponding to each individual patient were found, but there were no differences between patients with mild versus severe histologic recurrence. (From Rosen HR, Marousek G, Chou S. A longitudinal analysis of T cell epitope coding regions of hepatitis C virus after liver transplantation. Transplantation 2002;74:209–16; with permission.) Clinics in Liver Disease 2003 7, 107-125DOI: (10.1016/S1089-3261(02)00073-9)

Fig. 4 Levels of HCV RNA as measured by Taqman PRC (log-transformed values) and the fibrosis score at the time of the 5-year routine biopsy after liver transplantation. The error bars indicate standard deviations. (From Giguo M, Roque-Afonso AM, Falissard B, Penin F, Dussaix E, Feray C. Genetic clustering of hepatitis C virus strains and severity of recurrent hapatitis after liver transplantation. J Virol 2001:75:11292–7; with permission.) Clinics in Liver Disease 2003 7, 107-125DOI: (10.1016/S1089-3261(02)00073-9)

Fig. 5 Flow cytometric analysis of intrahepatic lymphocytes from (A) Patient with HCV-related liver failure. (B) Patient with amyloidosis (and histologically normal liver explant). Note the relative percentages of lymphocytes expressing T cell and NK markers and the decrease of NK and NKT cells in the HCV-infected patient. Clinics in Liver Disease 2003 7, 107-125DOI: (10.1016/S1089-3261(02)00073-9)

Fig. 6 Immune reconstitution of HCV-specific T cell immunity in a recipient treated pre-emtively with interferon α-2b ribavirin starting 2 weeks after liver transplantation and continued for 48 weeks. Using the IFN-γ ELISPOT assay with whole recombinant proteins, there is emergence of new CD4+ T cell responses at 2 months that inversely correlates with viral load (patient became HCV RNA negative in serum by 4 months post-LT). CD8+ T cell frequencies were determined by soluble HLA A2-HCV peptide tetramers (immunodominant core 131–140 and N53 1073–1081 peptides) after magnetic bead separation of purified CD8+ T cells. HCV viral load was assessed by b-DNA Quaniplex 3.0 (Bayer). Clinics in Liver Disease 2003 7, 107-125DOI: (10.1016/S1089-3261(02)00073-9)

Fig. 7 Intrahepatic and peripheral CD4+ T lymphocytes were expanded nonspecifically (for 10 days) from peripheral blood and from a 4 mm liver biopsy (6 months after liver transplantation) with anti-CD3:anti-CD4 (CD3,8) bispecific mAb that causes selective cytolysis of CD8+ lymphocytes (by bridging the CD8 molecules to the CD3 complex with concurrent activation and proliferation of residual CD3+CD4+ T cells). Phenotyping revealed significant differences in cell surface expression between both compartments, with enrichment for activated memory cells within the allograft. Clinics in Liver Disease 2003 7, 107-125DOI: (10.1016/S1089-3261(02)00073-9)

Fig. 8 Intrahepatic CD4+ T lymphocytes in (A) patient with mild typical allograft hepatitis caused by recurrent HCV (total Knodell histologic activity index, 5) and in (B) severe cholestatic HCV. Note the marked difference in Th1/Th2 polarization, with IL-4 production predominating in the latter patient. CD4+ T lymphocytes have been expanded as described in Fig. 7. Clinics in Liver Disease 2003 7, 107-125DOI: (10.1016/S1089-3261(02)00073-9)

Fig. 9 (Top) Potential contributing factors in HCV recurrence. (Bottom) conceptual paradigm for HCV-specific T cell responses in shaping viral replication and allograft injury post-LT. Patients responding to antiviral therapy demonstrate viral clearance concurrent with early emergence of CD4+ and CD8+ T cells. Patients who demonstrate mild histologic recurrence despite high viral loads demonstrate lack HCV-specifc T cells as assessed by ELISPOT and tetramer analyses. Clinics in Liver Disease 2003 7, 107-125DOI: (10.1016/S1089-3261(02)00073-9)

Fig. 9 (Top) Potential contributing factors in HCV recurrence. (Bottom) conceptual paradigm for HCV-specific T cell responses in shaping viral replication and allograft injury post-LT. Patients responding to antiviral therapy demonstrate viral clearance concurrent with early emergence of CD4+ and CD8+ T cells. Patients who demonstrate mild histologic recurrence despite high viral loads demonstrate lack HCV-specifc T cells as assessed by ELISPOT and tetramer analyses. Clinics in Liver Disease 2003 7, 107-125DOI: (10.1016/S1089-3261(02)00073-9)